These data suggested that PDLIM2 repression may suppress tumor-infiltrating lymphocyte (TIL) activation and/or render lung cancer cells resistant to chemotherapeutic drugs and cytotoxic T cells (CTLs), including those CTLs released from the PD-1 checkpoint by PD-1 blockade. The gene discussed is PDLIM2; the disease is neoplasm.